Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SGM-101 fluorescence-guided imaging in neoadjuvant-treated pancreatic cancer surgery
NL-OMON56065Phase 2Recruiting
- Sponsor
- Leiden University Medical Center
- Start
- Feb 2024
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of sgm-101 in pancreatic cancer (PC) and pancreatic adenocarcinoma (PDAC) (2 arms), sponsored by Leiden University Medical Center. Primary endpoint: Performance of SGM-101 for fluorescence-guided imaging during pancreatic resection. Started Feb 2024; status: recruiting.
02
Drugs
sgm-101
03
Conditions
pancreatic cancer (PC)pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NL-OMON56065.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON56065.